Last year, Rutger Zietsma was named as one of In Vivo’s Rising Leaders thanks in part to his work driving the development and implementation of the NeuroMotor Pen, a handheld device that can be easily used by patients and clinicians to detect a variety of neurological abnormalities. At the time, Zietsma discussed the importance of selecting the right individuals to bring on board for a fledgling business and how the impact of a poor decision can be severe.
Manus Neurodynamica: Catching Up With A 2022 Rising Leader
2022 was a turbulent year for start-ups, especially in medtech. However, Rutger Zietsma has persisted, refocused and is ready for further success with his company, Manus Neurodynamica.
More from Rising Leaders
• By
It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.
• By
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
• By
Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech.
• By
“I'm a strong believer in creating the right mix between young ambitious people and pairing them up with someone experienced,” says Jeroen Bakker, who is focused on biotech company creation at Seed Investments, Novo Holdings.
More from Leadership
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.
• By
A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.